Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway

Due to the lack of known therapeutic targets for triple-negative breast cancer (TNBC), chemotherapy is the only available pharmacological treatment. Pirarubicin (tetrahydropyranyl Adriamycin, THP) is the most commonly used anthracycline chemotherapy agent. However, TNBC has a high recurrence rate af...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mian, Yang, Jiu, Lv, Wuwu, Wang, Shuanglian, Du, Tao, Zhang, Kejing, Wu, Yuhui, Feng, Xueping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2022
Materias:
Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738866/
https://www.ncbi.nlm.nih.gov/pubmed/34935899
http://dx.doi.org/10.1042/BSR20210245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8738866/
https://www.ncbi.nlm.nih.gov/pubmed/34935899
http://dx.doi.org/10.1042/BSR20210245

Ejemplares similares